Advicenne S.A. (ALDVI.PA)
EUR 1.67
(0.12%)
EUR 1.67
(0.12%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.15 Million EUR | 85.98% |
| 2022 | 2.39 Million EUR | -10.86% |
| 2021 | 2.68 Million EUR | 30.41% |
| 2020 | 2.06 Million EUR | 3.14% |
| 2019 | 1.99 Million EUR | 68.0% |
| 2018 | 1.18 Million EUR | 47.58% |
| 2017 | 806.3 Thousand EUR | 200.86% |
| 2016 | 268 Thousand EUR | 145.87% |
| 2015 | 109 Thousand EUR | -94.1% |
| 2014 | 1.84 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 884.5 Thousand EUR | 0.0% |
| 2024 Q1 | 884.5 Thousand EUR | 13.11% |
| 2023 Q1 | 851 Thousand EUR | 8.27% |
| 2023 Q2 | 1.58 Million EUR | 85.78% |
| 2023 Q3 | 782 Thousand EUR | -50.54% |
| 2023 FY | 4.45 Million EUR | 85.98% |
| 2023 Q4 | 782 Thousand EUR | 0.0% |
| 2022 Q3 | 518.49 Thousand EUR | -66.66% |
| 2022 Q1 | 953 Thousand EUR | -27.03% |
| 2022 FY | 2.39 Million EUR | -10.86% |
| 2022 Q4 | 786 Thousand EUR | 51.59% |
| 2022 Q2 | 1.55 Million EUR | 63.17% |
| 2021 FY | 2.68 Million EUR | 30.41% |
| 2021 Q4 | 1.3 Million EUR | 30.99% |
| 2021 Q3 | 997 Thousand EUR | -26.91% |
| 2021 Q2 | 1.36 Million EUR | 57.14% |
| 2021 Q1 | 868 Thousand EUR | -10.14% |
| 2020 Q4 | 966 Thousand EUR | 3.21% |
| 2020 Q1 | 809.5 Thousand EUR | -10.65% |
| 2020 Q3 | 936 Thousand EUR | -14.6% |
| 2020 Q2 | 1.09 Million EUR | 35.39% |
| 2020 FY | 2.06 Million EUR | 3.14% |
| 2019 Q3 | 730.5 Thousand EUR | -3.5% |
| 2019 Q1 | 557 Thousand EUR | 180.88% |
| 2019 FY | 1.99 Million EUR | 68.0% |
| 2019 Q4 | 906 Thousand EUR | 24.02% |
| 2019 Q2 | 757 Thousand EUR | 35.91% |
| 2018 Q4 | 198.3 Thousand EUR | 0.0% |
| 2018 Q3 | 198.3 Thousand EUR | -56.13% |
| 2018 Q1 | 452 Thousand EUR | -32.44% |
| 2018 Q2 | 452 Thousand EUR | 0.0% |
| 2018 FY | 1.18 Million EUR | 47.58% |
| 2017 Q4 | 669 Thousand EUR | 0.0% |
| 2017 Q2 | 587.5 Thousand EUR | 0.0% |
| 2017 Q1 | 587.5 Thousand EUR | 17.5% |
| 2017 FY | 806.3 Thousand EUR | 200.86% |
| 2017 Q3 | 669 Thousand EUR | 13.87% |
| 2016 FY | 268 Thousand EUR | 145.87% |
| 2016 Q1 | 440.5 Thousand EUR | 0.0% |
| 2016 Q2 | 440.5 Thousand EUR | 0.0% |
| 2016 Q3 | 500 Thousand EUR | 13.51% |
| 2016 Q4 | 500 Thousand EUR | 0.0% |
| 2015 FY | 109 Thousand EUR | -94.1% |
| 2014 FY | 1.84 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 32.091% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 31.811% |
| Adocia SA | 2.15 Million EUR | -46.558% |
| Aelis Farma SA | 9.05 Million EUR | 65.198% |
| Biophytis S.A. | - EUR | -Infinity% |
| genOway Société anonyme | 20.04 Million EUR | 84.281% |
| IntegraGen SA | 12.53 Million EUR | 74.867% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -950.214% |
| Neovacs S.A. | 533.41 Thousand EUR | -490.725% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -87.391% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -15817.357% |
| Sensorion SA | 4.74 Million EUR | 33.566% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -963.338% |
| TME Pharma N.V. | 17 Thousand EUR | -18435.294% |
| Valbiotis SA | 4.73 Million EUR | 33.425% |
| TheraVet SA | 1.07 Million EUR | -192.286% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -75.056% |
| argenx SE | 1.13 Billion EUR | 99.722% |
| BioSenic S.A. | 543 Thousand EUR | -480.295% |
| Celyad Oncology SA | 102 Thousand EUR | -2989.216% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 98.686% |
| Genfit S.A. | 28.56 Million EUR | 88.969% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -50.982% |
| Innate Pharma S.A. | 51.9 Million EUR | 93.929% |
| Inventiva S.A. | 17.47 Million EUR | 81.971% |
| MaaT Pharma SA | 2.22 Million EUR | -41.427% |
| MedinCell S.A. | 9.16 Million EUR | 65.6% |
| Nanobiotix S.A. | 30.05 Million EUR | 89.517% |
| Onward Medical N.V. | 532 Thousand EUR | -492.293% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 77.797% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -41.491% |
| Oxurion NV | 263 Thousand EUR | -1098.099% |
| Pharming Group N.V. | 245.31 Million EUR | 98.716% |
| Poxel S.A. | 1.98 Million EUR | -59.061% |
| GenSight Biologics S.A. | 1.26 Million EUR | -148.698% |
| Transgene SA | 1.18 Million EUR | -166.132% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.94% |
| Valneva SE | 153.71 Million EUR | 97.95% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 187.044% |